MedPath

Siplizumab

Generic Name
Siplizumab
Drug Type
Biotech
CAS Number
288392-69-8
Unique Ingredient Identifier
KUW1QG1ZM3
Indication

Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).

Clinical Trials
Related News

A Study of SIPLIZUMAB in AILD and LT Patients

Phase 1
Recruiting
Conditions
Liver Transplant Disorder
Primary Sclerosing Cholangitis
Autoimmune Liver Disease
Autoimmune Hepatitis
End Stage Liver DIsease
Cirrhosis, Liver
Interventions
First Posted Date
2024-06-12
Last Posted Date
2024-11-12
Lead Sponsor
Elizabeth C. Verna
Target Recruit Count
8
Registration Number
NCT06455280
Locations
🇺🇸

Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
Drug: Corticosteroids (CS)
First Posted Date
2024-04-15
Last Posted Date
2025-01-29
Lead Sponsor
ITB-Med LLC
Target Recruit Count
33
Registration Number
NCT06365437
Locations
🇸🇪

Skåne University Hospital, Malmö, Sweden

🇸🇪

Sahlgrenska University Hospital, Göteborg, Sweden

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 4 locations

A Study to Demonstrate the Safety and Efficacy of Siplizumab in the Treatment of Hidradenitis Suppurativa

Early Phase 1
Not yet recruiting
Conditions
Hidradenitis Suppurativa
Interventions
First Posted Date
2024-03-22
Last Posted Date
2025-01-29
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
12
Registration Number
NCT06326476

Siplizumab for Sickle Cell Disease Transplant

Phase 1
Recruiting
Conditions
Anemia, Sickle Cell
Interventions
Procedure: Exchange Transfusion
Procedure: Total Body Irradiation
Procedure: Stem Cell Infusion
First Posted Date
2023-10-12
Last Posted Date
2025-02-13
Lead Sponsor
Columbia University
Target Recruit Count
18
Registration Number
NCT06078696
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

A Study of TCD601 (siplizumab) in New Onset Type 1 Diabetes Patients

Phase 2
Active, not recruiting
Conditions
Diabetes Mellitus, Type 1
Interventions
Other: Placebo
First Posted Date
2023-09-06
Last Posted Date
2025-03-05
Lead Sponsor
ITB-Med LLC
Target Recruit Count
96
Registration Number
NCT06025110
Locations
🇧🇪

UZ Brussel, Brussel, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

🇮🇹

Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy

and more 23 locations

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Phase 2
Active, not recruiting
Conditions
Liver Transplantation
Interventions
Drug: TAC
Drug: Corticosteroids
First Posted Date
2023-08-31
Last Posted Date
2024-11-27
Lead Sponsor
ITB-Med LLC
Target Recruit Count
12
Registration Number
NCT06019507
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Huddinge, Sweden

Delayed Tolerance Through Mixed Chimerism

Phase 1
Recruiting
Conditions
Kidney Failure
Kidney Transplant; Complications
Chimera
Interventions
Other: Bone Marrow Transplant
Procedure: Peripheral Blood Stem Cell Collection
First Posted Date
2023-06-12
Last Posted Date
2024-06-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT05900401
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of TCD601 in de Novo Renal Transplant Recipients

Phase 2
Active, not recruiting
Conditions
Renal Transplantation
Interventions
Drug: TAC
Drug: Corticosteroids
First Posted Date
2022-12-30
Last Posted Date
2025-04-17
Lead Sponsor
ITB-Med LLC
Target Recruit Count
90
Registration Number
NCT05669001
Locations
🇺🇸

Scripps Green Hospital, La Jolla, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

University of California Davis Medical Center, Sacramento, California, United States

and more 24 locations

Siplizumab in T1DM

Phase 1
Active, not recruiting
Conditions
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2022-10-10
Last Posted Date
2024-08-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
120
Registration Number
NCT05574335
Locations
🇺🇸

Stanford School of Medicine: Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Stanford, California, United States

🇺🇸

Emory University School of Medicine: Emory & Children's Pediatric Research Center, Division of Endocrinology & Diabetes, Atlanta, Georgia, United States

🇺🇸

The University of Chicago: Duchossois Center for Academic Medicine-Hyde Park, Chicago, Illinois, United States

and more 16 locations

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Phase 2
Active, not recruiting
Conditions
Kidney Transplantation
Interventions
First Posted Date
2021-03-17
Last Posted Date
2025-04-17
Lead Sponsor
ITB-Med LLC
Target Recruit Count
18
Registration Number
NCT04803006
Locations
🇺🇸

UCSF Connie Frank Transplant Center, San Francisco, California, United States

🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Cooperman Barnabas Medical Center, Livingston, New Jersey, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy